As your partner we are taking all the necessary steps to make sure your drug development continues without any disruptions in the process. Moving your molecule forward during COVID-19 doesn’t need to be stressful or difficult. We continue to learn and have found reliable ways to adapt our practices and offerings to reduce the learning curve for our customers. In the short videos below, we answer some common questions being asked during COVID-19 regarding:
- What’s different in selecting a CRO during COVID-19
- Can WuXi AppTec help keep my program moving forward
- How does the contractual process work if I need to transfer my study
- What do I need to consider when reopening my lab post COVID-19
Watch our team of experts discuss common unknowns when moving your molecule through the drug development process during COVID-19.
Executive Director of Toxicology
Sue provides over 30 years of preclinical toxicology experience and manages the study director group within the toxicology department. She will be discussing what things you should consider when selecting a CRO during COVID-19.
Dr. Xin Zhang
Vice President, Customer Experience Management & Strategic Projects
Xin’s experience spans various fields focusing on establishing the client-oriented operational structure, multi-functional management, business strategies, and implementation. Xin currently leads strategic projects and customer experience focusing on cross division partnerships and alliances. He will be explaining how WuXi AppTec is prepared to help your program move forward.
Vice President of International Sales & Field Marketing
Ed has more than 25 years of successful performance in senior sales leadership, sales, marketing, public relations and client services in the pharmaceutical industry. Ed will speak to service contracts and how to get the process started weather it’s a new project or transferring a program to another site.
Dr. Mark Walker
Senior Technical Director of Toxicology
With more than 25 years of preclinical toxicology experience, Dr. Mark Walker provides professional focus and strength in primate toxicology and integrative toxicology program design and regulatory interactions for Investigational New Drug (IND) applications. He will discuss what it takes to ramp up your lab post COVD-19.
WuXi AppTec provides a portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.
If you have further questions about how WuXi AppTec can help you during COVID-19, contact us here.